[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Pharmacology](https://durgical.com/en/pharmacology/) › [Ebola monoclonal antibodies](https://durgical.com/en/pharmacology/classes/ebola-monoclonal-antibodies/) › Ansuvimab

[Pharmacology](https://durgical.com/en/pharmacology/) · [Ebola monoclonal antibodies](https://durgical.com/en/pharmacology/classes/ebola-monoclonal-antibodies/)

# Ansuvimab

A single human monoclonal antibody against the Ebola virus glycoprotein. WHO strongly recommends it for Ebola virus disease.

Updated 2026-11-01

- Class: [Ebola monoclonal antibodies](https://durgical.com/en/pharmacology/classes/ebola-monoclonal-antibodies/)
- Target: Zaire ebolavirus surface glycoprotein (GP)
- ATC code: J06BD04
- WHO Model List of Essential Medicines

Also called: mAb114

## Mechanism of action

Ansuvimab is a human IgG1 monoclonal antibody that binds the receptor-binding domain of the GP1 subunit of the Ebola virus glycoprotein. This stops the glycoprotein from binding NPC1, the host receptor the virus needs to enter cells, so viral entry is blocked.

- Binds the receptor-binding domain of glycoprotein GP1
- GP1 cannot bind the host receptor NPC1
- Viral entry into cells is blocked
- Viral load falls; survival improves when given early

## Pharmacokinetics

**Absorption**
Intravenous infusion

**Elimination**
Like other IgG antibodies, slow catabolism over weeks

## Indications

- Ebola virus disease caused by Zaire ebolavirus, in adults and children, including newborns of infected mothers [Viral haemorrhagic fevers (Ebola and others) →](https://durgical.com/en/conditions/viral-haemorrhagic-fevers/)

## Adverse effects

### Common

- Fever and chills
- Fast heart rate and fast breathing
- Diarrhoea and vomiting
- Low blood pressure

### Serious (rare, important)

- Hypersensitivity reactions, including infusion-associated events, during or after the infusion

## Contraindications

- Severe hypersensitivity to ansuvimab

## Key interactions

**Live Ebola (Zaire) vaccine**
The antibody may reduce the vaccine's efficacy; timing follows vaccination guidelines

## What is monitored

- Vital signs during and after the infusion
- Fluid balance, electrolytes and kidney function as part of supportive care

## Administration and safety

- Single intravenous infusion
- Given in a treatment centre with full infection prevention and control precautions

## Nursing care

- Use full personal protective equipment for Ebola care
- Watch for fever, low blood pressure or breathlessness during the infusion
- Continue optimized supportive care: fluids, electrolytes, nutrition, pain relief, treatment of malaria and other co-infections

## Pregnancy and breastfeeding

Ebola is life-threatening for mother and fetus, and treatment is not withheld because of pregnancy; the antibody can cross the placenta.

## Memory aid

ANSUVIMAB = «one antibody, one shot» against Zaire Ebola.

## Test yourself

Think of the answer, then tap the question to see it.

## What does ansuvimab bind?

The surface glycoprotein of Zaire ebolavirus.

## Which Ebola-related diseases does ansuvimab not cover?

Sudan virus disease and Bundibugyo virus disease.

## What is the code name of ansuvimab?

mAb114.

[Add to my cards (3)](https://durgical.app/estudiar/?add=/en/pharmacology/ansuvimab/)

## Related drugs

- [Atoltivimab + maftivimab + odesivimab](https://durgical.com/en/pharmacology/atoltivimab-maftivimab-odesivimab/)

## Related conditions

- [Viral haemorrhagic fevers (Ebola and others)](https://durgical.com/en/conditions/viral-haemorrhagic-fevers/)

[← Back to the class: Ebola monoclonal antibodies](https://durgical.com/en/pharmacology/classes/ebola-monoclonal-antibodies/)

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: [Ebola disease](https://www.who.int/news-room/fact-sheets/detail/ebola-disease) (World Health Organization, 2025); [ATCDDD - ATC/DDD Index](https://atcddd.fhi.no/atc_ddd_index/?code=J06BD04) (WHO Collaborating Centre for Drug Statistics Methodology, 2026); Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed., ch. 62 (McGraw Hill, 2023).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/pharmacology/ansuvimab/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/pharmacology/ansuvimab/